Professor Nina Tirnitz-Parker is the Director of the Curtin Health Innovation Research Institute, Co-Director of the Liver Cancer Collaborative (LCC, www.livercancercollaborative.au), and Board Director of GESA. The LCC is a multidisciplinary consortium of hepatologists, oncologists, interventional radiologists, computational biologists, and cancer researchers working towards personalised precision medicine for liver cancer patients. Their novel patient-matched research pipeline includes: (i) comprehensive tissue and serum biobanking, (ii) genomic and transcriptomic characterisation, (iii) patient-derived, precision-bioprinted organoid drug screening, and (iv) cross-linking research pipeline data with clinical outcomes in a comprehensive database.